- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
127 Cards in this Set
- Front
- Back
|
study of the mechanism of action of drugs within the body and how drugs produce their effects in the body
|
Pharmacodynamics
|
|
study of drug reactions in the body that are unanticipated or unusual, and may have a hereditary basis for the response
|
Pharmacogenetics
|
|
study of drug actions as they move through the body; the way the body absorbs, distributes, metabolizes, and excretes drugs; mathe
|
pharmacokinetics
|
|
pharmacology
|
study of biologically active compunds; how they react in the body & how the body reacts to them
|
|
study of drugs used to prevent, treat or Dx. disease
|
pharmacotherapeutics
|
|
pharmacy
|
preparation & dispensing of drugs
|
|
toxicology
|
study of harmful or poisonous effects of drugs
|
|
3 drug names
|
1. chemical name
2. generic name 3. trade name |
|
chemical name
|
scientific name, describes the atomic & molecular structure of a Rx
|
|
generic name
|
nonproprietary name, abbreviation of the chemical name
|
|
trand name
|
brand name, trade name, selected by the pharmaceutical company that made the drug
|
|
receptors
|
*protein molecules with one or more binding sites, located on the cell membrane.
* receive a signal from the body's chemicals: neurotransmitters, hormones, enzymes *signal will cause a molecular even on the inside of the cell to occur |
|
drug enchance
|
agonist
|
|
drug that diminish
|
partial agonist
|
|
drug that blocks
|
antagonist
|
|
affinity
|
attraction between a drug and a receptor
|
|
high affinity
|
drug will bind easily to the receptor
|
|
low affinity
|
requires a higher concentration of the drug to get a therapeutic response
|
|
drug potency
|
amount of Rx required to produce a therapeutic response
|
|
effective dose
|
amount of Rx that produces a therapeutic reponse in 50% of the people taking it
|
|
toxic dose (TD)
|
amount of drug that produces asdverse effects in 50% of the people taking it
|
|
therapeutic index
|
margin of safety; ratio between the toxic dose and the effective dose
|
|
the safer the drug is considered to be; in general nonprescription drugs have much higher therapeutic index than prescription drugs
|
the higher the therapeutic Index
|
|
schedule drugs classes
|
1. schedule 1:C-1
2. Schedule 2: C-II 3. schedule 3: C-III 4. Schedule 4: C-IV 5. Schedule 5: C-V |
|
C-I
|
higher abuse potential; not legal; no acceptable medical use; no prescriptions available
example: Heroin, LSD, cocaine, marijuana, methaqualone |
|
C-II
|
higher abuse potential and severe dependence liability; current, a accepted medical use; prescription drug-signed, not stamped prescription; 30 day supply no refills
example: Opium, morphine, cocamethadone |
|
C-III
|
less abuse potential; low-moderate physical dependence; high psychological dependence; by prescription only, expires within 6 months; max 5 refills on one script
examples: amphetamines, codeine, barbiturated, valium, Xanax, anabolic steriods |
|
C-IV
|
less abuse potential than C-II drugs; accepted medical use; limited physical and psychological dependence; written or verbal prescription; expires in 6 months; max 5 refils on one script
examples: chloral hydrate, meptrobamate, paraldehyde, phenobarbital |
|
C-V
|
limited abuse potential; accepted medical use; small amounts of narcotics used as antitussives(chough medicine) or antidiarrheals; may not need a prescription but must be recorded as a transaction
|
|
routes drugs take to get into the body
|
enteral - GI tract, PO, rectum, under tongue, or held in the cheeks
parenteral- different means like injected into the veins, arteries, muscles, spinal cord, or under the skin, inhaled through lungs, transdermally through the skin via oinment or patch |
|
promoting a change in cellular function
|
agonist
|
|
blocks the receptor usually resulting in no direct biological effect
|
antagonist
|
|
* refers to molecule with a center of three-dimensional asymmetry.
|
Chiral
|
|
molecules which are not superimposable on (cannot be made to coincide with) their mirror image. achiral molecules can be superimposed on its mirror image.
|
Chirality
|
|
molecules having opposite shapes) are pairs of molecules existing in forms that are mirror images of each other (right-& left-hand) but that cannot be superimposed
|
Enantiomers
|
|
molecule has 2 asymmetric centers, the molecule is referred to as
|
diasteriomer
|
|
item appears identical to its image in a mirror it is said to be
|
achiral
|
|
All molecules are _______ when they have one stereogenic (asymmetric) carbon.
|
chiral
|
|
transport of solid matter or liquid into the cell utilizing a coated vacuole or vesicle.
|
Endocytosis Definition
|
|
Transport of materials out of a cell using a vesicle that first engulfs the material and then is extruded through an opening in the cell membrane.
|
Exocytosis Definition
|
|
Most drug have molecular weights between:
|
100 and 1000
|
|
General term having to do with actions of the body on the drug:
|
pharmacokinetics
|
|
Most common mechanism of drug permeation
|
passive diffusion
|
|
Drug with this ionization property most likely to diffuse from intestine (pH 8.4) to blood (pH 7.4)
1. weak acid (pKa 7.4) 2. weak base (pKa 8.4) 3. weak acid (pKa 8.4) 4. weak base (pKa 6.4) 5. weak acid (pKa 6.4) |
4. weak base (pKa 6.4)
recall that the pH would have to be 6.4 for 1/2 of the molecules to accept a proton and become charged. At pH 8.4 (intestine), the hydrogen ion concentration is too low for this weak base to accept a proton and become charged. |
|
Weak organic acid, pKa 6.5. Percent ionization at pH 7.5
a 1% b 10% c 50% d 90% e 99% |
D: 90%
For a one order of magnitude change (6.5 to 7.5-one power of 10), the choice is 10% or 90%; in the case of an acid, a pH higher than the pKa promotes increased ionization. Your score is: 60%. |
|
Drug delivery method LEAST suitable for long term (days to weeks) slow release.
a pellet implant under the skin (subcutaneous) b time release capsule c i.m. injection of a drug- oil suspension d transdermal patch e none of the above |
b time release capsule
extended release is common, but not over a days to weeks time frame. |
|
Mechanism(s) of drug permeation:
A lipid diffusion B aqueous diffusion C use of carrier molecules D endocytosis and exocytosis E all of the above |
E all of the above
|
|
Increasing ionization at pH ABOVE pKa:
A weak acid B weak base |
A weak acid
when pH=pk, 50% of the molecules are ionized. For the weak acid to lose more protons (charged), the pH needs to be above the pKa. |
|
Drug-transport system described as "energy requiring":
A glomerular filtration B facilitated diffusion C active transport D B & C E A, B & C |
C active transport
|
|
Bond type that is seen in some drug-receptor interactions and tends to very strong, often nearly irreversible:
A hydrophobic B electrostatic C covalent D A & C E B & C |
C covalent
|
|
Pharmacological antagonists:
A cause receptor down regulation B prevent binding of other molecules to the receptor by their binding to the receptor C atropine (blocks ACh action on the heart D A & B E B & C |
E B & C
|
|
Faster drug absorption:
A lung B stomach |
A lung
|
|
Most important factor influencing drug absorption rate following intramuscular injection:
A needle diameter B rate of administration C injection site blood flow D injection volume |
C injection site blood flow
|
|
Saturable transport system(s):
A facilitated diffusion B passive diffusion C active transport D A & B E A & C |
A and C
|
|
Passive diffusion (aqueous or lipid environment): most common
Active transport: important for some drugs, particularly larger molecules. |
Permeation
|
|
within large aqueous components (e.g.,interstitial space, cytosol)
across epithelial membrane tight junctions across endothelial blood vessel lining through aqueous pores: allows diffusion of molecules with molecular weights up to 20,000 -- 30,000. |
Aqueous diffusion
|
|
represents a tendency for molecules to move in the direction of higher concentration to lower concentration in accord with random molecular motion. A traditional way of thinking about this is to imagine a fluid-filled container which is two sections divided by an imaginary plane. The solution on one side is more concentrated in terms of some dissolved substance that is the solution on the other side of the boundary plane.
|
driving force
|
|
describes passive movement molecules down its concentration gradient.
|
Fick's Law
|
|
Plasma protein-bound drugs cannot permeate through
|
aqueous pores
|
|
Charged drugs will be influenced by _____________ {membrane potentials, important in renal, trans-tubular transport}
|
electric field potentials
|
|
Most important barrier for drug permeation due to:
many lipid barriers separating body compartments |
Lipid diffusion
|
|
Ionization state of the drug is an important factor: charged drugs diffuse-through lipid environments with _______________.
|
difficulty
|
|
Lipid: aqueous drug partition coefficients described the ease with which a drug moves between _________ and __________ environments
|
AQUEOUS AND LIPID
|
|
uncharged form
|
lipid-soluble
|
|
charged form
|
aqueous-soluble, relatively lipid-insoluble (does not pass biological membranes easily)
|
|
a weak acid at acid pH will be more ______________because it is uncharged and uncharged molecules move more readily through a lipid (nonpolar) environment, like the some membrane, than charged molecules
|
lipid-soluble
|
|
a weak base at alkaline pH will be more _____________because at alkaline pH a proton will dissociate from molecule leaving it uncharged and again free to move through lipid membrane structures
|
lipid-soluble
|
|
________ diffusion depends on adequate lipid solubility
|
LIPID
|
|
Drug ionization reduces a drug's ability to cross a _________ bilayer.
|
LIPID
|
|
___________IS a neutral molecule that can form a cation (positively charged) by combining with a proton
|
WEAK BASE
|
|
___________is a neutral molecule that dissociates into an anion (negatively charged) and a proton (a hydrogen ion)
|
WEAK ACID
|
|
Peptides, amino acids, glucose are examples of molecules then enter cells through _______________mechanisms
|
special carrier
|
|
______________ describes an energy requiring process which is saturable, meaning that transport is probably against the concentration gradient and involves a finite number of carriers, hence the process must be saturable when all carrier sites are filled.
|
Active transport
|
|
limited number of carrier sites--once those sites are filled, transport rates cannot be increased.
|
Saturable
|
|
A property of carrier systems is that process is subject to
|
inhibition by other small molecules
|
|
Entry into cells by very large substances (e.g., iron vitamin B12 -- each complexed with its binding protein -- movement across intestinal wall into the blood)
|
Endocytosis
|
|
Following neuronal electrical activation of nerve endings, two steps may be initiated:
|
Storage vesicles containing neurotransmitter fuse with cell membranes followed by
release or diffusion of contents into the extracellular region. |
|
Incomplete absorption following oral drug administration is common:
For example -- only 70% of a digoxin dose reaches systemic circulation. factors are: |
poor GI tract absorption
digoxin (Lanoxin, Lanoxicaps) --- metabolism by gastrointestinal flora |
|
not be well absorbed --cannot cross cell membrane lipid component
|
Very hydrophilic drugs
|
|
soluble (hydrophobic) drugs may not be soluble enough to cross a water layer near the cell membrane.
|
Excessively lipid
|
|
To increase excretion
|
change the urinary pH to favor the charged form of the drug since charged form cannot be readily reabsorbed (they cannot readily pass through biological membranes)
|
|
excreted faster in alkaline pH (anion form favored)
|
Weak acids
|
|
excreted faster in acidic pH (cation form favored)
|
Weak bases
|
|
Body fluids where pH differences from blood pH favor trapping or reabsorption:
|
stomach contents
small intestine breast milk aqueous humor (eye) vaginal secretions prostatic secretions |
|
fetal pH is higher or lower than maternal pH
|
lower
|
|
Most convenient, most economical route of administration of drug
|
oral
|
|
Oral Administration
Disadvantages: |
emesis (drug irritation of the gastrointestinal mucosa)
digestive enzymes/gastric acidity destroys the drug unreliable or inconsistent absorption due to food or other drug effects metabolism of the drug by gastrointestinal flora |
|
Factors determining rate of drug effect onset
|
Primary factor:
Rate & absorption extent by GI tract Absorption Site: mainly small intestine because of large surface area Drug ionization state: nonionized (lipid-soluble) forms favor absorption |
|
Drug ionization state:
nonionized (lipid-soluble) forms favor absorption weak acids may be highly ionized in the alkaline intestinal pH (not favoring absorption) but this effect is counterbalanced by the large surface-area effect drugs which are weak acids are readily absorbed in the stomach |
Drug ionization state
|
|
Drugs absorbed from the GI tract passes through the portal venous system then through the liver and finally into the systemic circulation when drugs interact with receptors in target tissues.
Extensive hepatic metabolism/extraction result in minimal drug delivery to the systemic circulation for certain agents. Drugs with large first pass effect exhibit significant differences in pharmacological effects comparing oral vs. IV administration Examples: propranolol lidocaine |
First-Pass Effect
|
|
Transdermal Administration
Advantages: |
sustained, therapeutic plasma levels (reduced peaks/valleys associated with intermittent drug administrations)
Avoids continuous infusion technique difficulties Low side effect incidence (smaller doses) Generally good patient compliance |
|
Factors contributing to reliable transdermal drug absorption:
|
molecular weight < 1000
pH range 5-9 in aqueous medium no histamine-releasing action daily drug requirement <10 mg |
|
Low _______ administration of drug may allow the drug to enter the systemic circulation without passing through the liver
|
rectal
|
|
Proximal rectum administration: Absorption into superior hemorrhoidal veins then enters the portal venous system then to the liver (possible first pass hepatic effect) and finally into the systemic circulation
Low rectal administration of drug may allow the drug to enter the systemic circulation without passing through the liver Generally unpredictable pharmacological responses for the above reasons Rectal mucosal irritation possible |
Rectal Administration
|
|
Ensures active drug absorption
subcutaneously intramuscular injection: more rapid/predictable than oral administration route only route of administration acceptable for: uncooperative patients unconscious patients |
Parenteral Administration
|
|
Parenteral Administration
Factors the determine rate of systemic absorption: |
absorbing capillary membrane surface area
drug solubility in interstitial fluid aqueous channels (vascular endothelium) promote high diffusion rates of drugs, independent of their lipid solubility |
|
Advantages of IV administration
|
rapid/precise blood drug levels obtained (e.g., no first-pass effect)
Irritant drugs: more comfortably administered (blood vessels relatively insensitive); drug rapidly diluted (particularly if administered into large forearm vein) |
|
First-pass Elimination:
Transport sequence: |
across the gut wall into the portal circulation
portal blood transports of the drug to the liver the drug may then reach the systemic circulation bioavailability may be affected by steps 1 -- 3 drug metabolism may occur in the intestinal wall or in the blood drug metabolism (potentially extensive) may occur in liver liver may excrete drug into the bile overall process that contributes to bioavailability reduction is the first-pass lost or elimination |
|
Some drugs which have relatively low _______________ are not given orally because of concern of metabolite toxicity -- lidocaine is an example (CNS toxicity, convulsions)
|
bioavailability
|
|
Some drugs that exhibit high or low extraction by the liver are given orally.
Some examples -- desipramine (Norpramin), imipramine (Tofranil), meperidine (Demerol), propranolol (Inderal), amitriptyline (Elavil, Endep), isoniazid (INH). |
high
|
|
High extraction ratio drugs show interpatient bioavailability variation because all of sensitivity to:
|
hepatic function
blood flow hepatic disease (intrahepatic or extrahepatic circulatory shunting) |
|
Drugs poorly extracted by the liver
|
phenytoin (Dilantin)
diazepam (Valium) digitoxin (Crystodigin) chlorpropamide (Diabinese) theophylline Tolbutamide (Orinase) warfarin (Coumadin) |
|
Avoiding the first-pass effect:
|
sublingual (e.g. nitroglycerin)-- direct access to systemic circulation
transdermal use of suppositories in the lower rectum {if suppositories move upward, absorption may occur through the superior hemorrhoidal veins, which lead to the liver} inhalation: first-pass pulmonary loss by excretion or metabolism may occur. |
|
Pulmonary uptake:
|
Effects peak arterial concentration
May serve as a reservoir, enabling transport of drug into systemic circulation |
|
First-pass pulmonary effect magnitude not affected by:
|
spontaneous respiration
controlled ventilation apnea |
|
is the ratio between the amount of drug in body (dose given) and the concentration of the drug (C) measured in blood or plasma.
|
Volume of distribution (Vd)
|
|
Vd formula
|
(amount of drug in body)/C where C is the concentration of drug in blood or plasma.
|
|
Factors influencing the volume of distribution:
|
drug pKa
extent of drug-plasma protein binding partition coefficient of the drug in fat (lipid solubility) Vd may be affected by: patient's gender patient's age patient's disease patient's body composition Example of a poorly lipid soluble agent with a Vd about equal to extracellular fluid volume: nondepolarizing neuromuscular blocking drugs. |
|
_____________ is especially important for insuring appropriate long-term drug dosing -- correct steady-state drug concentrations
|
Clearance
|
|
Clearance of a given drug is usually constant over the therapeutic concentration range because:
|
Drug elimination systems are not saturated -- therefore the absolute rate of elimination is a linear function of the drug's plasma concentration.
Drug elimination is therefore usually a first-order kinetic process-- a constant fraction of the drug is eliminated per unit time. Some drugs (e.g., ethanol) exhibit zero order kinetics -- a constant amount of drug is eliminated per unit time. {Clearance is variable} |
|
__________ most important organs for unchanged drug/drug metabolites elimination
|
kidney
|
|
Water-soluble compounds exhibit more efficient renal excretion compared to ___________compounds (emphasizing the importance of metabolic conversion of lipid-soluble drugs to water-soluble metabolites)
|
lipid soluble
|
|
Factors in renal excretion
|
Glomerular filtration
Tubular secretion (active process Passive tubular reabsorption |
|
Factors in renal excretion:
Glomerular filtration-- important considerations: |
Fraction of free drug (compared to protein-bound drug)--when a drug is bound to protein it is not filtered
Glomerular filtration rate |
|
Factors in renal excretion:
Tubular secretion (active process)-- important considerations: |
Drug/metabolite selectivity
|
|
Factors in renal excretion
Passive tubular reabsorption-- important considerations: |
Enhanced lipid solubility favors reabsorption {lipid-soluble agents more readily cross renal tubular epithelial cell membrane thus entering pericapillary fluid}
Example: thiopental (highly lipid-soluble): completely reabsorbed -- minimal unchanged drug excreted in urine Renal tubular reabsorption rate influenced by: pH rate of renal tubular urine flow weak acid or weak base drug/drug metabolite pKa compared to urinary pH |
|
drug elimination following metabolic transformation of the parent drug to metabolites
Since elimination is not "saturable", elimination is typically first order and directly proportional to drug concentration: |
Hepatic clearance
|
|
Other factors affecting renal clearance:
|
renal disease
rates of filtration depend on: volume filtered in the glomerulus unbound drug concentration in plasma (plasma protein-bound drug is not filtered) drug secretion rates: extent of drug-plasma protein binding carrier saturation drug transfer rates across tubular membranes rate of drug delivery to secretory sites changes in plasma protein concentration blood flow number of functional nephrons |
|
Factors affecting hepatic clearance:
|
Drug delivery to hepatic elimination sites may be rate-limiting for certain drugs:
also called flow dependent elimination: in this case most of the drug in the blood is eliminated on the first pass of the drug through the organ these drugs are termed "high-extraction" extent of plasma protein-bound drug blood flow (affects clearance on drugs with high extraction ratios). |
|
Changes in the intrinsic clearance
Social factors: |
Tobacco smoke induces some hepatic microsomal drug metabolizing enzyme isoforms (CYP1A1, CYP1A2, and possibly CYP2E1)
Chronic ethanol use induces CYP2E1 |
|
Changes in the intrinsic clearance
Dietary considerations |
Grapefruit juice contains chemicals that are potent inhibitors of CYP3A4 localized in the intestinal wall mucosa
Cruciferous vegetables such as brussels sprouts, cabbage, cauliflower and hydrocarbons present in charcoal-broiled meats can induce CYP1A2. Calcium present in dairy products can chelate drugs including commonly used tetracyclines and fluoroquinone antibiotics. |
|
Changes in the intrinsic clearance
age: |
Neonates have reduced hepatic metabolism and renal excretion due to relative organ immaturity. On the other hand, elderly patients exhibit differences in absorption, hepatic metabolism, renal clearance and volume of distribution.
|
|
time required to decrease the amount of drug in body by 1/2 during elimination (or during a constant infusion).
|
Half-life: (t1/2)
|
|
Factors affecting t1/2:
|
disease states-- affects volume of distribution and clearance
half-life changes secondary to changes in plasma protein binding. |
|
Drug Accumulation
|
With repeating drug doses, the drug will accumulate in the body until dosing ceases.
Practically: accumulation will be observed if the dosing interval is less than 4 half-lives. Accumulation: inversely proportional to the fraction of the dose lost in each dosing interval Accumulation factor = 1/Fraction lost in one dosing interval = 1/(1 - fraction remaining) For example, the accumulation factor for a drug given once every half-life: 1/0.5 equals 2. |
|
fraction of unchanged drug that reaches systemic circulation following administration (by any Route of Administration)
|
Bioavailability
Examples: IV administration: bioavailability = 1 Other routes of administration = < 1 |
|
Major factors that reduce bioavailability to less than 100%:
|
incomplete absorption
first-pass effect (liver metabolizes drug before drug reaches systemic circulation) |